NCT05262218View on ClinicalTrials.gov

Therapeutic Effect of PBF-680 in Patients With COPD

PHASE2CompletedINTERVENTIONAL
Enrollment

174

Participants

Timeline

Start Date

December 20, 2021

Primary Completion Date

February 27, 2024

Study Completion Date

April 9, 2024

Conditions
COPD
Interventions
DRUG

PBF-680 10mg

PBF-680 10mg administered orally once a day

DRUG

Placebo

Placebo administered orally once a day

Trial Locations (7)

Unknown

Complejo Hospitalario de Navarra, Pamplona

Hospital Bellvitge, Barcelona

Hospital Clinic, Barcelona

Hospital del Mar, Barcelona

Hospital German Trias i Pujol, Barcelona

Hospital Sant Pau, Barcelona

Hospital Vall d´hebron, Barcelona

All Listed Sponsors
collaborator

Scope International AG

INDUSTRY

lead

Palobiofarma SL

INDUSTRY

NCT05262218 - Therapeutic Effect of PBF-680 in Patients With COPD | Biotech Hunter | Biotech Hunter